U.S. Markets close in 1 hr 54 mins
  • S&P 500

    3,931.71
    -67.13 (-1.68%)
     
  • Dow 30

    33,508.38
    -438.72 (-1.29%)
     
  • Nasdaq

    11,003.57
    -236.36 (-2.10%)
     
  • Russell 2000

    1,809.98
    -30.24 (-1.64%)
     
  • Crude Oil

    73.93
    -3.00 (-3.90%)
     
  • Gold

    1,779.70
    -1.60 (-0.09%)
     
  • Silver

    22.22
    -0.20 (-0.88%)
     
  • EUR/USD

    1.0467
    -0.0031 (-0.2931%)
     
  • 10-Yr Bond

    3.5570
    -0.0420 (-1.17%)
     
  • Vix

    21.79
    +1.04 (+5.01%)
     
  • GBP/USD

    1.2143
    -0.0051 (-0.4201%)
     
  • USD/JPY

    137.0340
    +0.3490 (+0.2553%)
     
  • BTC-USD

    16,978.19
    -86.64 (-0.51%)
     
  • CMC Crypto 200

    399.78
    -2.03 (-0.50%)
     
  • FTSE 100

    7,521.39
    -46.15 (-0.61%)
     
  • Nikkei 225

    27,885.87
    +65.47 (+0.24%)
     

Lumos Pharma to Participate in Upcoming Investor Conferences

Lumos Pharma, Inc.
Lumos Pharma, Inc.

AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the 34th Annual Roth Conference and the Maxim 2022 Virtual Growth Conference in March.

Event:

34th Annual Roth Conference – March 13-15

Presentation:

Live fireside chat March 14th at 10:30 AM PDT / 1:30 PM EDT

Webcast link:

Here

Event:

Maxim 2022 Virtual Growth Conference – March 28-30

Presentation:

Pre-recorded presentation available beginning March 28th at 9:00 AM (EDT)

Webcast link:

Here on the M-Vest conference platform

The webcasts for each presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay of each presentation will be also be available. Please contact your Roth or Maxim salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.